Tags

Type your tag names separated by a space and hit enter

Continuous glucose monitoring.

Abstract

Real-time continuous glucose monitoring (RT-CGM) has the potential to revolutionise the care and treatment of individuals with type 1 diabetes (T1D). During the past three years, several devices to measure the interstitial fluid intermittently or continuously have been developed and approved as an adjunct to blood glucose monitoring for use in individuals with T1D. Original studies using these earlier devices showed promise in lowering HbA1c in selected individuals with suboptimal control (1). The first randomised controlled trial with a subcutaneous continuous sensor demonstrated a significant decrease in HbA1c in adult and paediatric patients with poor metabolic control using the RT-CGM device continuously for 3 months compared with the self-monitoring of blood glucose (SMBG) control group (2). Recent randomised controlled trials clearly demonstrated that RT-CGM can significantly reduce HbA1c. Additionally, retrospective use of CGM data can positively affect metabolic control in both type 1 and type 2 diabetes.

Authors+Show Affiliations

Atlanta Diabetes Associates77 Collier Rd. Suite 2080, Atlanta, GA 30309, USA. bode001@aol.comNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20377658

Citation

Bode, B W., and T Battelino. "Continuous Glucose Monitoring." International Journal of Clinical Practice. Supplement, 2010, pp. 11-5.
Bode BW, Battelino T. Continuous glucose monitoring. Int J Clin Pract Suppl. 2010.
Bode, B. W., & Battelino, T. (2010). Continuous glucose monitoring. International Journal of Clinical Practice. Supplement, (166), 11-5. https://doi.org/10.1111/j.1742-1241.2009.02272.x
Bode BW, Battelino T. Continuous Glucose Monitoring. Int J Clin Pract Suppl. 2010;(166)11-5. PubMed PMID: 20377658.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Continuous glucose monitoring. AU - Bode,B W, AU - Battelino,T, PY - 2010/4/10/entrez PY - 2010/8/18/pubmed PY - 2010/10/12/medline SP - 11 EP - 5 JF - International journal of clinical practice. Supplement JO - Int J Clin Pract Suppl IS - 166 N2 - Real-time continuous glucose monitoring (RT-CGM) has the potential to revolutionise the care and treatment of individuals with type 1 diabetes (T1D). During the past three years, several devices to measure the interstitial fluid intermittently or continuously have been developed and approved as an adjunct to blood glucose monitoring for use in individuals with T1D. Original studies using these earlier devices showed promise in lowering HbA1c in selected individuals with suboptimal control (1). The first randomised controlled trial with a subcutaneous continuous sensor demonstrated a significant decrease in HbA1c in adult and paediatric patients with poor metabolic control using the RT-CGM device continuously for 3 months compared with the self-monitoring of blood glucose (SMBG) control group (2). Recent randomised controlled trials clearly demonstrated that RT-CGM can significantly reduce HbA1c. Additionally, retrospective use of CGM data can positively affect metabolic control in both type 1 and type 2 diabetes. SN - 1368-504X UR - https://www.unboundmedicine.com/medline/citation/20377658/Continuous_glucose_monitoring_ DB - PRIME DP - Unbound Medicine ER -